Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827563 · ClinicalTrials.gov registry record
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
A clinical trial, sponsored by University of Chicago.
- Terminated
- Registry status
- 50
- Enrollment target
NCT04827563 is a clinical trial that was terminated before completion, run by University of Chicago. The registered enrollment target is 50 participants.
The verdict
NCT04827563 was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Interventions
- OTHER Blood Tests
- DIAGNOSTIC_TEST Echocardiogram
- OTHER Quality of Life Assessment
- DEVICE EndoPAT
- DEVICE Blood Pressure Cuff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04827563
The ClinicalTrials.gov registry entry for NCT04827563 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Blood Tests is the first listed.
NCT04827563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04827563 about?
NCT04827563 is a clinical study titled "Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib". This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the hea...
What is the current status of trial NCT04827563?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2021-03-22. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT04827563?
The interventions under investigation include: Blood Tests (OTHER), Echocardiogram (DIAGNOSTIC_TEST), Quality of Life Assessment (OTHER), EndoPAT (DEVICE), Blood Pressure Cuff (DEVICE).
Who is sponsoring clinical trial NCT04827563?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.